BioMerieux : Résultats semestriels au 30 juin 2021 - 1er September 2021
September 01, 2021 at 03:32 pm EDT
Share
H1 2021 Results & Outlook
September 1st, 2021
P I O N E E R I N G D I A G N O S T I C S
DISCLAIMER
This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.
The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.
This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.
AGENDA
OVERVIEW of bioMérieux
H1 2021 ACTIVITY REVIEW
H1 2021 FINANCIAL RESULTS
2021 OUTLOOK
B I O M É R I E U X
3
AT A GLANCE - 2020 FIGURES
55 YEARS OF EXPERTISE IN IN VITRO DIAGNOSTICS
CLINICAL
INDUSTRIAL
APPLICATIONS
APPLICATIONS
85% of revenues
15% of revenues
Sales amounting to
About 12,800
93% of
1,900 people
Strong commitment
€3.1 billion
employees worldwide
international sales
dedicated to R&D
to innovation 13%
of sales invested in R&D
B I O M É R I E U X
MISSION, STRATEGY AND STRENGTHS
PIONEERING DIAGNOSTICS
To improve public health, focused
on the fight against infectious diseases
MICROBIOLOGY
MOLECULAR BIOLOGY
Two leadership positions in both clinical
Leader in the syndromic diagnosis
and industrial applications
of infectious diseases
Broad & complementary range of
Wide & balanced geographic
footprint
solutions
IMMUNOASSAYS
Specialized high medical value offer
Solid financial situation
B I O M É R I E U X
Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.
Attachments
Original document
Permalink
Disclaimer
BioMérieux SA published this content on 01 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 September 2021 19:31:10 UTC.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
BIOMÉRIEUX 
